ALVOCash now, dilution later
Alvotech just told the market it’s starting an underwritten public offering of its ordinary shares, aiming to raise about $125 million. On top of that, the underwriters can grab up to another 15% of the shares sold if demand is strong enough. Classic capital-markets move: more cash for the company, more share count for everyone else to stare at.
Why investors care
This is the kind of announcement that can make a stock wobble even before the deal is priced. Why? Because share offerings often mean dilution, which can press on per-share value in the short term.
A few practical takeaways:
- All the shares are being sold by Alvotech itself, so the company gets the proceeds.
- The deal is still subject to market conditions, so size and timing can still change.
- The extra 15% greenshoe means the final haul could creep higher if bankers smell demand.
Big picture
For a biotech company, this is often just the price of staying funded and keeping the machine running. But for shareholders, it’s also the moment where the “growth story” gets a little more expensive in stock terms.